OpenLB
Open Library of Bioscience
Advanced Search
Cureus
Mar, 2022;14 (3): e23452.

Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.

Sharina C Macapagal, Hayoung Lee, Javaria Abdul Jabbar, Anna Caroline Fjorden, Irene Tresa Joseph, Ramanpreet Kaur, Jihan A Mostafa
Author Information
  1. Sharina C Macapagal: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  2. Hayoung Lee: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  3. Javaria Abdul Jabbar: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  4. Anna Caroline Fjorden: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  5. Irene Tresa Joseph: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  6. Ramanpreet Kaur: Research, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
  7. Jihan A Mostafa: Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
PMID: 35481332 DOI: 10.7759/cureus.23452

Abstract

The central dilemma in treating patients with refractory or relapsed classical Hodgkin lymphoma (RRHL) is the developed resistance to chemotherapy. In recent years, significant advances have been made with the introduction of targeted immunotherapy such as brentuximab vedotin (BV) and nivolumab (NV). As monotherapy, BV and NV have demonstrated high response rates but with an opportunity for disease progression. In other studies, BV or NV is given in combination with chemotherapy as a bridge to hematopoietic stem cell transplantation for curative therapy. This review will investigate the effect of BV and NV as single agents, in combination with each other, or given concurrently with chemotherapy on the response and survival rate of patients with RRHL.

Keywords

antibody-drug conjugate brentuximab vedotin immune-checkpoint inhibitors immunotherapy nivolumab refractory and relapsed hodgkin lymphoma

References

  1. Br J Haematol. 2020 May;189(3):e86-e90 [PMID: 32048731]
  2. Blood. 2021 Aug 12;138(6):427-438 [PMID: 33827139]
  3. Lancet Haematol. 2020 Sep;7(9):e660-e670 [PMID: 32853585]
  4. Leuk Lymphoma. 2019 Feb;60(2):367-375 [PMID: 30032683]
  5. Ther Adv Hematol. 2021 Aug 19;12:20406207211038181 [PMID: 34434538]
  6. J Hematol. 2020 Apr;9(1-2):30-32 [PMID: 32362983]
  7. Pathology. 2020 Jan;52(1):154-165 [PMID: 31699300]
  8. Turk J Pediatr. 2019;61(5):671-676 [PMID: 32104998]
  9. Hemasphere. 2020 Jun 08;4(3):e401 [PMID: 32647803]
  10. J Clin Oncol. 2018 May 10;36(14):1428-1439 [PMID: 29584546]
  11. Ann Hematol. 2017 Jul;96(7):1219-1220 [PMID: 28434018]
  12. World J Stem Cells. 2021 Jun 26;13(6):503-520 [PMID: 34249225]
  13. Ann Oncol. 2019 Apr 1;30(4):612-620 [PMID: 30657848]
  14. Eur J Haematol. 2020 Jun;104(6):581-587 [PMID: 32107795]
  15. Ann Hematol. 2020 Feb;99(2):301-307 [PMID: 31844933]
  16. Blood. 2018 Mar 15;131(11):1183-1194 [PMID: 29229594]
  17. Cancers (Basel). 2019 Jul 29;11(8): [PMID: 31362369]
  18. Blood. 2016 Sep 22;128(12):1562-6 [PMID: 27432875]
  19. Syst Rev. 2021 Mar 29;10(1):89 [PMID: 33781348]
  20. JCO Oncol Pract. 2021 Feb;17(2):64-71 [PMID: 33434064]
  21. Eur J Cancer. 2017 Nov;85:67-77 [PMID: 28892775]
  22. Int J Hematol. 2021 Mar;113(3):404-412 [PMID: 33392974]
  23. Bone Marrow Transplant. 2019 Jul;54(7):1168-1172 [PMID: 30700792]
  24. J Clin Oncol. 2012 Jun 20;30(18):2183-9 [PMID: 22454421]
  25. Jpn J Clin Oncol. 2020 Oct 22;50(11):1265-1273 [PMID: 32776097]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0BVNVpatientsrefractoryrelapsedHodgkinlymphomaRRHLchemotherapyimmunotherapybrentuximabvedotinnivolumabresponsegivencombinationcentraldilemmatreatingclassicaldevelopedresistancerecentyearssignificantadvancesmadeintroductiontargetedmonotherapydemonstratedhighratesopportunitydiseaseprogressionstudiesbridgehematopoieticstemcelltransplantationcurativetherapyreviewwillinvestigateeffectsingleagentsconcurrentlychemotherapy onsurvivalrateEfficacyBrentuximabVedotinNivolumabRefractoryRelapsedLymphoma:SystematicReviewantibody-drugconjugateimmune-checkpointinhibitorshodgkin

Similar Articles

Cited By